The Drug Cell (TDC) marks a major breakthrough in the field of cell therapies in Europe. This new French alliance brings together key players in biotechnology and innovation to develop scalable and accessible therapeutic solutions. As part of the France 2030 initiative, TDC aims to advance research, development, and industrial deployment, with the first clinical trials planned by 2030 and market entry expected in 2034.
This pioneering ecosystem integrates cutting-edge technologies such as automation, artificial intelligence, and digital manufacturing, ensuring real-time quality control and enhanced scalability. Among the major innovations, Digital Twin technology will be implemented from the early stages, enabling real-time monitoring and optimization of treatments before patient testing.
The Drug Cell unites nine leading French biotech and innovation players, including Etablissement Français du Sang (EFS), Centre d’Étude des Cellules Souches/I-Stem, Gpi France, Carroucell, EVerZom, MGA Technologies, University of Montpellier, CHU of Montpellier, and CHU of Rennes. These organizations will collaborate to establish France and Europe as leaders in regenerative medicine.
For more details, read the full press release.
In the Same Category
Jean-Noël Barrot at Maison MGA
Industry is a matter of sovereignty. We were delighted to welcome the Minister for Foreign Affairs, Jean-Noël Barrot, to the Maison MGA in Civrieux d’Azergues today. The visit centred on a key issue: how can France remain a major industrial nation in an increasingly...
Jean-Noël Barrot visits Maison MGA: a tribute to French industrial expertise
On Friday, June 5, 2026, we had the pleasure of welcoming Jean-Noël Barrot, Minister for Europe and Foreign Affairs, to our Civrieux-d’Azergues site as part of his visit to the Lyon area focused on major industrial, technological, and healthcare challenges. This visit...